PMID- 16597592
OWN - NLM
STAT- MEDLINE
DCOM- 20061005
LR  - 20220318
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 108
IP  - 3
DP  - 2006 Aug 1
TI  - Retrospective comparison of reduced-intensity conditioning and conventional 
      high-dose conditioning for allogeneic hematopoietic stem cell transplantation 
      using HLA-identical sibling donors in myelodysplastic syndromes.
PG  - 836-46
AB  - In this multicenter retrospective study, the outcomes of 836 patients with 
      myelodysplastic syndrome (MDS) who underwent transplantation with a human 
      leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 
      types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and 
      standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In 
      multivariate analysis, the 3-year relapse rate was significantly increased after 
      RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P = 
      .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC 
      group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of 
      progression-free and overall survivals were similar in both groups (39% after SMC 
      vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In 
      conclusion, the lower 3-year NRM after RIC is encouraging, since these patients 
      were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and had more 
      adverse pretransplantation variables. However, based on the higher risk of 
      relapse, patients with no contraindications for SMC should not receive RIC 
      outside of prospective randomized trials, which are needed to establish the 
      position of RIC-based transplantation in the treatment of patients with MDS.
FAU - Martino, Rodrigo
AU  - Martino R
AD  - Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous 
      University of Barcelona, Spain. rmartino@santpau.es
FAU - Iacobelli, Simona
AU  - Iacobelli S
FAU - Brand, Ronald
AU  - Brand R
FAU - Jansen, Thekla
AU  - Jansen T
FAU - van Biezen, Anja
AU  - van Biezen A
FAU - Finke, Jurgen
AU  - Finke J
FAU - Bacigalupo, Andrea
AU  - Bacigalupo A
FAU - Beelen, Dietrich
AU  - Beelen D
FAU - Reiffers, Jossy
AU  - Reiffers J
FAU - Devergie, Agnes
AU  - Devergie A
FAU - Alessandrino, Emilie
AU  - Alessandrino E
FAU - Mufti, Ghulam J
AU  - Mufti GJ
FAU - Barge, Renee
AU  - Barge R
FAU - Sierra, Jorge
AU  - Sierra J
FAU - Ruutu, Tapani
AU  - Ruutu T
FAU - Boogaerts, Marc
AU  - Boogaerts M
FAU - Falda, Michele
AU  - Falda M
FAU - Jouet, Jean-Pierre
AU  - Jouet JP
FAU - Niederwieser, Dieter
AU  - Niederwieser D
FAU - de Witte, Theo
AU  - de Witte T
CN  - Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of 
      the European Blood and Marrow Transplantation Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20060404
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - HLA Antigens
MH  - Hematopoietic Stem Cell Transplantation/*methods/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/mortality/*therapy
MH  - Recurrence
MH  - Retrospective Studies
MH  - Siblings
MH  - Survival Analysis
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
EDAT- 2006/04/07 09:00
MHDA- 2006/10/06 09:00
CRDT- 2006/04/07 09:00
PHST- 2006/04/07 09:00 [pubmed]
PHST- 2006/10/06 09:00 [medline]
PHST- 2006/04/07 09:00 [entrez]
AID - S0006-4971(20)52733-X [pii]
AID - 10.1182/blood-2005-11-4503 [doi]
PST - ppublish
SO  - Blood. 2006 Aug 1;108(3):836-46. doi: 10.1182/blood-2005-11-4503. Epub 2006 Apr 
      4.